Drug Trial Radar · NCT04541108
Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies
Last checked: Nov 19, 2026Latest source record: May 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
15
Planned (sponsor's estimate)
Start
Jul 26, 2021
Primary completion
Dec 2031
Study completion Dec 2031
Sponsor
- Lead sponsor
- Presage BiosciencesIndustry
- Sponsor type
- Industry
- First posted
- Sep 9, 2020
Design
- Study type
- Interventional
- Phase
- Early phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multi-center, open-label Phase 0 Master Protocol designed to study the localized pharmacodynamics (PD) of anti-cancer therapies within the tumor microenvironment (TME) when administered intratumorally in microdose quantities via the CIVO device in patients with surface accessible solid tumors for which there is a scheduled surgical intervention. CIVO stands for Comparative In Vivo Oncology. Multiple substudies will include specified investigational agents and combinations to be evaluated.
Conditions
- Solid Tumor
Interventions
RilvegostomigBiological
Intratumoral microdose injection by the CIVO device.
VolrustomigBiological
Intratumoral microdose injection by the CIVO device.
SabestomigBiological
Intratumoral microdose injection by the CIVO device.
PembrolizumabBiological
Intratumoral microdose injection by the CIVO device.
AZD9592Biological
Intratumoral microdose injection by the CIVO device
AZD9592 + RilvegostomigCombination product
Intratumoral microdose injection by the CIVO device
AZD9592 + VolrustomigCombination product
Intratumoral microdose injection by the CIVO device
AZD9592 + SabestomigCombination product
Intratumoral microdose injection by the CIVO device
AZD9592 + PembrolizumabCombination product
Intratumoral microdose injection by the CIVO device
Primary outcomes
What the sponsor says the trial is designed to measure.
- Quantification of Selected Pharmacodynamic Biomarkers as Specified in Substudies by IHC, ISH, and/or Spatial Biology PlatformsTime frame: 4 hours-7 days after microdose injection
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
LSU Health Sciences Center - Shreveport
Shreveport, Louisiana
Montefiore Medical Center
The Bronx, New York
University of North Carolina
Chapel Hill, North Carolina
UC Health
Cincinnati, Ohio
Oregon Health & Science University (OHSU)
Portland, Oregon
University of Pennsylvania
Philadelphia, Pennsylvania
Sarah Cannon Research Institute
Charleston, South Carolina
MUSC Hollings Cancer Center
Charleston, South Carolina
University of Washington
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.